

August 23, 2021



Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the World Orphan Drug Congress USA 2022 Conference, to be held from August 25-27, 2022.

Dr. David Young, CEO and Chairman of Processa will deliver a presentation titled “Balancing the Benefit-Risk of an Orphan Drug: Case Studies.”

Presentation Details:

Date: Wednesday, August 25, 2021

Time: 1:30 PM Eastern Time

Website: <https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm>

About Processa Pharmaceuticals, Inc.

Our mission is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need conditions. We are a development company, not a discovery company, that seeks to identify and develop drugs for patients who need better treatment options than presently exist for their medical condition. To increase the probability of development success, our pipeline only includes drugs which have previously demonstrated some efficacy in the targeted population or a drug with very similar pharmacological properties has been shown to be effective in the population.

We currently have three drugs in various stages of clinical development: PCS499 for Ulcerative Necrobiosis in Phase 2B; PCS3117 for metastatic pancreatic cancer and non-small cell lung cancer in Phase 2B; and PCS6422 for metastatic colorectal cancer and breast cancer in Phase 1B. The PCS12852 IND for the treatment of gastroparesis will be submitted in 3Q2021.

Members of the Processa development team throughout their careers have been involved with more than 30 FDA drug approvals (including drug products targeted to orphan disease conditions), more than 100 FDA meetings, and two FDA regulatory science contracts. For more information, visit the company’s website at www.ProcessaPharma.com.


For More Information:

Michael Floyd

mfloyd@processapharma.com

(301) 651-4256

James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com



Source: Processa Pharmaceuticals, Inc.